Evidence map›Paper›PMID 31138593›Full record

ArticleBMJ case reports2019

Acute retinal necrosis in a patient with remote severe herpes simplex encephalitis.

Takaaki Kobayashi, Poorani Sekar, Jeffery Meier, Judy Streit

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Ocular manifestations of herpes simplex virus.Current opinion in ophthalmology · 2019
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Takaaki KobayashiInternal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.ORCID http://orcid.org/0000-0003-4643-4798
Poorani SekarInternal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Jeffery MeierInternal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Judy StreitInternal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
University of Iowa Hospitals and Clinics · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 60-year-old man with a history of severe herpes simplex virus type 1 (HSV-1) encephalitis 2 years prior presented with acute onset of visual loss in the left eye. Dilated funduscopic examination showed retinitis and occlusive vasculitis with retinal necrosis. PCR of the vitreous fluid was positive for HSV-1, and he was diagnosed with acute retinal necrosis (ARN) due to HSV-1. The patient was treated with intravenous acyclovir and intravitreous foscarnet for 2 weeks, followed by high dose oral valacyclovir for 2 weeks. He was subsequently placed on planned life-long suppressive valacyclovir. His case demonstrates that acute visual loss concomitant with or subsequent to HSV-1 encephalitis warrants suspicion of ARN. Prompt therapy with effective antiviral medication is necessary to reduce the risk of sight-threatening complications. Chronic suppression with oral antiviral therapy after ARN is recommended to prevent involvement of the contralateral eye, though there is no consensus on the duration and dosage of antivirals.

Indexed as

Acute DiseaseAcyclovirAntiviral AgentsDiagnosis, DifferentialEncephalitis, Herpes SimplexEye Infections, ViralFoscarnetHerpesvirus 1, HumanHumansIntravitreal InjectionsMaleMiddle AgedOphthalmoscopesRare DiseasesRetinal Necrosis Syndrome, AcuteTreatment OutcomeAcyclovirAntiviral AgentsFoscarnetValacyclovirinfectious diseasesophthalmology

Identifiers

PMID31138593
PMCPMC6557359
OpenAlexW2947096447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.